Human immunodeficiency virus type 1 neutralization by a single molecule of V3-targeted antibody

Microbiology and Immunology

Volumn 46, Issue 12, 2002, Pages 857-862

  Harada, Shinji ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti V3 antibody; HIV 1; Neutralization

Indexed keywords

MONOCLONAL ANTIBODY; THROMBOSPONDIN; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN DOMAIN; STEREOSPECIFICITY; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS ADSORPTION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 0036912786     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2002.tb02773.x     Document Type: Article

References (17)

1. Armstrong, S.J., McInerney, T.L., McLain, L., Wahren, B., Hinkula, J., Levi, M., and Dimmock, N.J. 1996. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J. Gen. Virol. 77: 2931-2941.
2. Cecilia, D., KewalRamani, V.N., O'Leary, J., Volsky, B., Nyambi, P., Burda, S., Xu, S., Littman, D.R., and Zolla-Pazner, S. 1998. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J. Virol. 72: 6988-6996.
3. Dragic, T. 2001. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 82: 1807-1814.
4. Dulbecco, R., Vogt, M., and Strickland, A.G.R. 1956. A study of the basic aspects of neutralization of two animal viruses, Western equine encephalitis virus and poliomyelitis virus. Virology 2: 162-205.
5. Foda, M., Harada, S., and Maeda, Y. 2001. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity. Microbiol. Immunol. 45: 521-530.
6. Harada, S., Koyanagi, Y., and Yamamoto, N. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229: 563-566.
7. Harada, S., Koyanagi, Y., and Yamamoto, N. 1985. Infection of human T-lymphotropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): Chronological studies of early events. Virology 146: 272-281.
8. Jackson, N.A.C., Levi, M., Wahren, B., and Dimmock, N.J. 1999. Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions. J. Gen. Virol. 80: 225-236.
9. Kimpton, J., and Emerman, M. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
10. Maeda, Y., Foda, M., Matsushita, S., and Harada, S. 2000. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1α. J. Virol. 74: 1787-1793.
11. Masuda, T., Matsushita, S., Kuroda, M.J., Kannagi, M., Takatsuki, K., and Harada, S. 1990. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. J. Immunol. 145: 3240-3246.
12. Matsushita, S., Robert-Guroff, M., Rusche, J., Koito, A., Hattori, T., Hoshino, H., Javaherian, K., Takatsuki, K., and Putney, S. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62: 2107-2114.
13. McBride, W.D. 1959. Antigenic analysis of polioviruses by kinetic studies of serum neutralization. Virology 7: 45-58.
14. Morizono, K., and Harada, S. 1998. Human immunodeficiency virus type 1 (HIV-1) infection and transcytosis activity of a HIV-1 susceptible clone from HeLa cell. Microbiol. Immunol. 42: 313-320.
15. Song, W., Yahara, S., Maeda, Y., Yusa, K., Tanaka, Y., and Harada, S. 2001. Enhanced infection of an X4 strain of HIV-1 due to capping and colocalization of CD4 and CXCR4 induced by capsianoside G, a diterpene glycoside. Biochem. Biophys. Res. Commun. 283: 423-429.
16. Zhu, P., Olson, W.C., and Roux, K.H. 2001. Structural flexibility and functional valence of CD4-IgG2 (PRO 542): Potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J. Virol. 75: 6682-6686.
17. Zwart, G., Langeduk, H., Van Der Hoek, L., DeJong, J., Wolfs, T.F.W., Ramautarsing, C., Bakker, M., DeRonde, A., and Goudsmit, J. 1991. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 181: 481-489.